期刊
CURRENT ATHEROSCLEROSIS REPORTS
卷 15, 期 6, 页码 -出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11883-013-0326-8
关键词
HDL cholesterol; Genetics; Cardiovascular disease; Atherosclerosis; Mendelian randomization; Genome-wide association; Apolipoprotein A-I; ATP-binding cassette transporter A1; Lecithin-cholesterol acyltransferase; Phospholipid transfer protein; Cholesteryl ester transport protein; Scavenger receptor class B type 1; Endothelial lipase
资金
- AstraZeneca
- Aegerion
- Genzyme
- Isis Pharmaceuticals
- Roche
- Pfizer
- Eli Lilly
- MSD
- Cerenis
Prospective epidemiological studies have consistently reported an inverse association between HDL cholesterol (HDL-C) levels and the risk of cardiovascular disease (CVD). However, large intervention trials on HDL-C-increasing drugs and recent Mendelian randomization studies have questioned a causal relationship between HDL-C and atherosclerosis. HDL-C levels have been shown to be highly heritable, and the combination of HDL-C-associated SNPs in recent large-scale genome-wide association studies (GWAS) only explains a small proportion of this heritability. As a large part of our current understanding of HDL metabolism comes from genetic studies, further insights in this research field may aid us in elucidating HDL functionality in relation to CVD risk. In this review we focus on the question of whether genetically defined HDL-C levels are associated with risk of atherosclerosis. We also discuss the latest insights for HDL-C-associated genes and recent GWAS data.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据